Want $1 million in retirement? Invest $10,000 in these 2 AI stocks and hold for 10 years.

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.
Yahoo Finance

A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recursion Pharmaceuticals ...
Yahoo Finance

Recursion’s REC-4881 Milestone And Cash Runway Shift Risk Reward Profile

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Recursion Pharmaceuticals (NasdaqGS:RXRX) reports positive clinical proof of concept for REC ...
InfoQ

MIT's Recursive Language Models Improve Performance on Long-Context Tasks

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Soroosh Khodami discusses why we aren't ready ...
Forbes

How Recursive AI Agents Can Help Turn Real-Time Data Into Smarter, Self-Improving Operations

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...
Benzinga.com

Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...
Reuters

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Forbes

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
STAT

Recursion CEO Chris Gibson out as company head after 12 years

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...